- Poster presentation
- Open access
- Published:
P032. Coenzyme Q-10 and migraine: a lovable relationship. The experience of a tertiary headache center
The Journal of Headache and Pain volume 16, Article number: A139 (2015)
Background
Coenzyme Q-10 (ubiquinone) is a small hydrophobic substance that acts as an electron carrier in the mitochondrial respiratory chain. Its main activity is to protect DNA, proteins and lipids from oxidative stress. In the literature, a role of brain oxidative metabolism in the pathogenesis of migraine has been hypothesized [1]. Few clinical trials are described using coenzyme Q-10 in migraine prophylaxis, even in pediatrics [2–4]. The aim of this work was to present our experience of migraine prevention, prescribing coenzyme Q-10 to 20 adult patients with migraine without aura.
Materials and methods
Patients were enrolled in a tertiary headache center and followed for a period of 60 days (visit 1 and visit 2). The dose of coenzyme Q-10 was 200 mg/day. Visual analogue scale (VAS) was used to measure pain.
Results
In our cohort, male/female ratio was 1:5, while the mean age was 32.1 years (range, 22-49 years). Patients had a relatively short history of disease (mean 5.6 years; range 2-18), indeed only 2 of them were on a first-line treatment whereas coenzyme Q-10 was the starting therapy for others. We noticed a significant reduction of the number of crises at visit 2 (mean 3.15 vs 0.9, p < 0.05), as well as VAS score (mean 6.65 vs 1.45, p < 0.05) and monthly days of headache (mean 6.3 vs 1.5, p < 0.05). No one showed side effects, body weight did not vary (mean 56.55 vs mean 56.65) and patients did not even experience drastic weight loss or gain. The drug was well tolerated with a mean satisfaction score of 7.65 (range, 0-10). Moreover, patients reported positive effects on fatigue.
Conclusions
Coenzyme Q-10 is a safe and effective therapy for migraine prophylaxis.
Written informed consent to publish was obtained from the patient(s).
Conflict of interest
None. This study did not receive any industry funding.
References
Montagna P, Sacquegna T, Cortelli P, Lugaresi E: Migraine as a defect of brain oxidative metabolism: a hypothesis. J Neurol. 1989, 236 (2): 124-125.
Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A, et al: A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011, 31 (8): 897-905.
Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, et al: Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005, 64 (4): 713-715.
Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, Silberstein SD: Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia. 2002, 22 (2): 137-141.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Pucci, E., Diamanti, L., Cristina, S. et al. P032. Coenzyme Q-10 and migraine: a lovable relationship. The experience of a tertiary headache center. J Headache Pain 16 (Suppl 1), A139 (2015). https://doi.org/10.1186/1129-2377-16-S1-A139
Published:
DOI: https://doi.org/10.1186/1129-2377-16-S1-A139